RIDGEBACK BIOTHERAPEUTICS
BiotechRIDGEBACK BIOTHERAPEUTICS is a biotechnology company focused on Infectious Disease.
FDA Novel Drug Designations
(2020)See 1 novel approval →
RIDGEBACK BIOTHERAPEUTICS's Key Drugs
RIDGEBACK BIOTHERAPEUTICS's core commercial portfolio centers on EBANGA, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
RIDGEBACK BIOTHERAPEUTICS's Recent FDA Approvals
New NDA/BLA approvals for RIDGEBACK BIOTHERAPEUTICS over the last two years — novel drugs only, excluding generics and label supplements.
RIDGEBACK BIOTHERAPEUTICS's Therapeutic Areas
RIDGEBACK BIOTHERAPEUTICS's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RIDGEBACK BIOTHERAPEUTICS's Top Competitors
RIDGEBACK BIOTHERAPEUTICS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RIDGEBACK BIOTHERAPEUTICS Pipeline Snapshot
RIDGEBACK BIOTHERAPEUTICS has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • EBANGA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-12-21
- Latest
- 2026-02-18
- Applications
- 1